Novolog Pharm (Israel) Performance
| NVLG Stock | 164.90 9.80 5.61% |
On a scale of 0 to 100, Novolog Pharm holds a performance score of 8. The company secures a Beta (Market Risk) of -0.22, which conveys not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Novolog Pharm are expected to decrease at a much lower rate. During the bear market, Novolog Pharm is likely to outperform the market. Please check Novolog Pharm's value at risk, downside variance, and the relationship between the maximum drawdown and potential upside , to make a quick decision on whether Novolog Pharm's current price movements will revert.
Risk-Adjusted Performance
8 of 100
Weak | Strong |
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Novolog Pharm Up 1966 are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. Despite somewhat weak basic indicators, Novolog Pharm sustained solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 176.4 M | |
| Total Cashflows From Investing Activities | -69.1 M |
Novolog |
Novolog Pharm Relative Risk vs. Return Landscape
If you would invest 14,933 in Novolog Pharm Up 1966 on November 2, 2024 and sell it today you would earn a total of 1,557 from holding Novolog Pharm Up 1966 or generate 10.43% return on investment over 90 days. Novolog Pharm Up 1966 is generating 0.2156% of daily returns and assumes 2.0656% volatility on return distribution over the 90 days horizon. Simply put, 18% of stocks are less volatile than Novolog, and 96% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Novolog Pharm Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Novolog Pharm's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Novolog Pharm Up 1966, and traders can use it to determine the average amount a Novolog Pharm's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1044
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | NVLG | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 2.07 actual daily | 18 82% of assets are more volatile |
Expected Return
| 0.22 actual daily | 4 96% of assets have higher returns |
Risk-Adjusted Return
| 0.1 actual daily | 8 92% of assets perform better |
Based on monthly moving average Novolog Pharm is performing at about 8% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Novolog Pharm by adding it to a well-diversified portfolio.
Novolog Pharm Fundamentals Growth
Novolog Stock prices reflect investors' perceptions of the future prospects and financial health of Novolog Pharm, and Novolog Pharm fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Novolog Stock performance.
| Return On Equity | 0.11 | |||
| Return On Asset | 0.0174 | |||
| Profit Margin | 0.03 % | |||
| Operating Margin | 0.05 % | |||
| Current Valuation | 1.45 B | |||
| Shares Outstanding | 508.7 M | |||
| Price To Book | 3.24 X | |||
| Price To Sales | 0.99 X | |||
| Revenue | 1.26 B | |||
| EBITDA | 115.92 M | |||
| Cash And Equivalents | 107.97 M | |||
| Cash Per Share | 0.31 X | |||
| Total Debt | 916 K | |||
| Debt To Equity | 0.60 % | |||
| Book Value Per Share | 0.86 X | |||
| Cash Flow From Operations | 83.39 M | |||
| Earnings Per Share | 0.08 X | |||
| Total Asset | 2.29 B | |||
About Novolog Pharm Performance
By analyzing Novolog Pharm's fundamental ratios, stakeholders can gain valuable insights into Novolog Pharm's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Novolog Pharm has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Novolog Pharm has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Novolog Ltd operates as a health logistics company in Israel. Novolog Ltd operates as a subsidiary of Pharm-Up Ltd. Novolog Ltd operates under Medical Care classification in Israel and is traded on Tel Aviv Stock Exchange.Things to note about Novolog Pharm Up performance evaluation
Checking the ongoing alerts about Novolog Pharm for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Novolog Pharm Up help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Novolog Pharm Up 1966 has accumulated 916 K in total debt with debt to equity ratio (D/E) of 0.6, which is about average as compared to similar companies. Novolog Pharm Up has a current ratio of 0.94, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Novolog Pharm until it has trouble settling it off, either with new capital or with free cash flow. So, Novolog Pharm's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Novolog Pharm Up sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Novolog to invest in growth at high rates of return. When we think about Novolog Pharm's use of debt, we should always consider it together with cash and equity. | |
| About 42.0% of Novolog Pharm outstanding shares are owned by corporate insiders |
- Analyzing Novolog Pharm's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Novolog Pharm's stock is overvalued or undervalued compared to its peers.
- Examining Novolog Pharm's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Novolog Pharm's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Novolog Pharm's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Novolog Pharm's stock. These opinions can provide insight into Novolog Pharm's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Novolog Stock analysis
When running Novolog Pharm's price analysis, check to measure Novolog Pharm's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novolog Pharm is operating at the current time. Most of Novolog Pharm's value examination focuses on studying past and present price action to predict the probability of Novolog Pharm's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novolog Pharm's price. Additionally, you may evaluate how the addition of Novolog Pharm to your portfolios can decrease your overall portfolio volatility.
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio |